Tumor Therapy with Targeted Atomic Nanogenerators
Top Cited Papers
- 16 November 2001
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 294 (5546), 1537-1540
- https://doi.org/10.1126/science.1064126
Abstract
A single, high linear energy transfer alpha particle can kill a target cell. We have developed methods to target molecular-sized generators of alpha-emitting isotope cascades to the inside of cancer cells using actinium-225 coupled to internalizing monoclonal antibodies. In vitro, these constructs specifically killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate cancer cells at becquerel (picocurie) levels. Injection of single doses of the constructs at kilobecquerel (nanocurie) levels into mice bearing solid prostate carcinoma or disseminated human lymphoma induced tumor regression and prolonged survival, without toxicity, in a substantial fraction of animals. Nanogenerators targeting a wide variety of cancers may be possible.Keywords
This publication has 13 references indexed in Scilit:
- Synthesis, Conjugation, and Radiolabeling of a Novel Bifunctional Chelating Agent for 225Ac Radioimmunotherapy ApplicationsBioconjugate Chemistry, 2000
- Evaluation of225Ac for Vascular Targeted Radioimmunotherapy of Lung TumorsCancer Biotherapy & Radiopharmaceuticals, 2000
- Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical MonitoringClinical Chemistry, 1999
- Comparison of 225actinium chelates: tissue distribution and radiotoxicityNuclear Medicine and Biology, 1999
- Improved in Vivo Stability of Actinium-225 Macrocyclic ComplexesJournal of Medicinal Chemistry, 1999
- An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operationApplied Radiation and Isotopes, 1999
- Radioimmunotherapy with alpha-emitting nuclidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- A Model of Cell Inactivation by Alpha-Particle Internal EmittersRadiation Research, 1993
- The feasibility of 225 Ac as a source of ??-particles in radioimmunotherapyNuclear Medicine Communications, 1993